Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Nuevolution AB
The company explained during its recent business review how its R&D organization is pursuing the strategic objectives of improving success rates, reducing cycle times and enabling access to novel drugs.
Lilly licenses non-opioid pain candidate from Centrexion. China’s Hansoh gets rights to inibelizumab from AstraZeneca spinout Viela for lead indication neuromyelitis optica as well as other autoimmune and blood cancer indications.
Amgen offered to buy its Scandinavian discovery partner for $166.8m to gain access to Nuevolution’s DNA-encoded drug discovery platform and nascent pipeline.
The Spanish derma specialist has agreed a research collaboration that could yield novel therapies for diseases such as psoriasis and atopic dermatitis.
- Other Names / Subsidiaries
- Nuevolution A/S